2022
Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS
O'Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, Nimmo C, Baldwin M, Boodhram R, Maharaj B, Amico KR, Naidoo K, Friedland G. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 325-332. PMID: 35195572, PMCID: PMC11077859, DOI: 10.1097/qai.0000000000002940.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAntitubercular AgentsDiarylquinolinesElectronicsHIV InfectionsHumansProspective StudiesSouth AfricaTreatment OutcomeTuberculosis, Multidrug-ResistantConceptsMDR-TB treatment outcomesResistance-associated variantsTreatment outcomesAntiretroviral therapyMDR-TBART adherenceMultidrug-resistant tuberculosis treatmentHIV treatment outcomesProspective cohort studyMultidrug-resistant tuberculosisEnd of treatmentTreatment of patientsSuccessful treatment outcomeElectronic dose monitoring devicesHIV/AIDSCohort studyClinical outcomesMultivariable analysisNovel regimensMedication adherenceAdherence thresholdTuberculosis treatmentTreatment completionLow adherenceDose monitoringAdherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntitubercular AgentsElectronicsHIVHIV InfectionsHumansProspective StudiesSouth AfricaTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear association
2016
Marking Time in the Global HIV/AIDS Pandemic
Friedland G. Marking Time in the Global HIV/AIDS Pandemic. JAMA 2016, 316: 145-146. PMID: 27404179, DOI: 10.1001/jama.2016.9006.Peer-Reviewed Original ResearchAcquired Immunodeficiency SyndromeCongresses as TopicHIV InfectionsHumansPandemicsResearchSouth Africa
2015
Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011
Cowell A, Shenoi SV, Kyriakides TC, Friedland G, Barakat LA. Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011. Journal Of Hospital Medicine 2015, 10: 608-614. PMID: 26130520, PMCID: PMC4560992, DOI: 10.1002/jhm.2409.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsCardiovascular DiseasesConnecticutFemaleHospital MortalityHumansInfectionsLiver DiseasesMaleMiddle AgedNeoplasmsConceptsHospital deathAIDS deathsHuman immunodeficiency virus-infected patientsHigher CD4 cell countsAIDS infectionAntiretroviral therapy eraNon-AIDS deathsNon-AIDS malignanciesCD4 cell countHIV viral loadVirus-infected patientsHuman immunodeficiency virusUrban teaching hospitalTimes greater likelihoodCardiovascular comorbiditiesTherapy eraCD4 countInpatient mortalityImmunodeficiency syndromeLiver diseaseUnderlying liverViral loadImmunodeficiency virusMedical recordsAntiretroviral era
2013
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnalgesics, OpioidAnti-Retroviral AgentsBuprenorphineDrug InteractionsHepatitis CHIV InfectionsHumansMethadoneOpiate Substitution TreatmentReceptors, OpioidConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadone
2006
Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications
Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 41: 563-572. PMID: 16652030, DOI: 10.1097/01.qai.0000219769.89679.ec.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDrug InteractionsHIV InfectionsHumansMethadoneConceptsPharmacokinetic drug interactionsOpioid agonist therapyDrug interactionsAgonist therapyAntiretroviral therapyAntiretroviral medicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesClass of agentsHIV/AIDSPharmacokinetic interaction studyAntiretroviral agentsCase seriesOpioid dependenceHIV treatmentTreatable diseaseHIV therapyClinical consequencesFollowing keywordsMethadoneTherapyClinical implicationsLanguage articlesMedications
2005
Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa
Mosam A, Cassol E, Page T, Bodasing U, Cassol S, Dawood H, Friedland GH, Scadden DT, Aboobaker J, Jordaan JP, Lalloo UG, Esterhuizen TM, Coovadia HM. Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa. AIDS 2005, 19: 441-443. PMID: 15750399, DOI: 10.1097/01.aids.0000161775.36652.85.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAfrica South of the SaharaAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountDeveloping CountriesDrugs, GenericHumansSarcoma, KaposiTreatment OutcomeViral LoadConceptsAntiretroviral therapyKaposi's sarcomaCopies/Generic antiretroviral therapyUndetectable viral loadActive antiretroviral therapyGeneric antiretroviral drugsAntiretroviral efficacyViral loadAntiretroviral drugsLog10 declineClinical experienceSarcomaTherapySaharan AfricaSub-Saharan AfricaHIVPatientsAIDSBaseline
2004
HAART for hospital health care workers--an innovative programme.
Uebel K, Friedland G, Pawinski R, Holst H. HAART for hospital health care workers--an innovative programme. South African Medical Journal 2004, 94: 423-7. PMID: 15250450.Peer-Reviewed Original ResearchAcquired Immunodeficiency SyndromeAntiretroviral Therapy, Highly ActiveConfidentialityCosts and Cost AnalysisHealth PersonnelHealth Plan ImplementationHealth Services AccessibilityHIV InfectionsHumansInfectious Disease Transmission, Patient-to-ProfessionalOccupational DiseasesPersonnel, HospitalSouth AfricaDrug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir
McCance‐Katz E, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir. American Journal On Addictions 2004, 13: 163-180. PMID: 15204667, DOI: 10.1080/10550490490436037.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultCytochrome P-450 Enzyme SystemDrug InteractionsFemaleHIV Protease InhibitorsHumansMaleMethadoneMethadyl AcetateNarcoticsNelfinavirSubstance-Related DisordersConceptsDrug interactionsMetabolite exposureClinical pharmacology studiesInjection drug usersNelfinavir concentrationsOpiate medicationsOpiate therapyMethadone exposureAntiretroviral medicationsHIV outcomesDay study periodPharmacology studiesDrug usersMethadoneNelfinavirLAAMStudy periodMedicationsMinimal overall changeProtease inhibitorsExposureToxicityOverall changeAntiretroviralsOpioids
2002
A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298)
Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298). AIDS Research And Human Retroviruses 2002, 18: 699-704. PMID: 12167276, DOI: 10.1089/088922202760072311.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-HIV AgentsCD4 Lymphocyte CountDouble-Blind MethodDrug Therapy, CombinationFemaleHumansLamivudineMaleMiddle AgedRNA, ViralStavudineZidovudineConceptsCD4 cell countStandard of careD4TViral loadWeek 12Copies/Cell countMedian baseline viral loadPhase II Randomized StudyD4T armDual nucleoside therapyAntiretroviral-naive patientsBaseline viral loadWeeks of monotherapyViral load reductionTreatment of patientsDevelopment of multidrugAntiretroviral-NaiveAntiviral suppressionNaive patientsCD4 cellsImmunologic effectsHIV infectionRandomized studyNucleoside therapyIncreasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study
Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, Friedland GH, O’Connor P, Selwyn PA. Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science & Medicine 2002, 55: 235-246. PMID: 12144138, DOI: 10.1016/s0277-9536(01)00167-8.Peer-Reviewed Original ResearchConceptsActive drug usersDrug users' adherenceDrug usersDrug treatmentMedical carePrimary careIntervention feasibility studySocial support structuresHealth advocatesUser adherenceTreatment program staffPeer-driven interventionHIV diseaseHIV infectionPatient adherenceSix-month studyHIV treatmentPhysician referralClinical appointmentsHIV therapeuticsCarePositive behavioral changesAdherencePeer pressureTreatment
1999
Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy
Lin P, González C, Griffith B, Friedland G, Calvez V, Ferchal F, Schinazi R, Shepp D, Ashraf A, Wainberg M, Soriano V, Mellors J, Colonno R. Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy. Antiviral Therapy 1999, 4: 21-28. PMID: 10682125, DOI: 10.1177/135965359900400103.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsDrug ResistanceHIV-1HumansPhenotypeRNA-Directed DNA PolymeraseStavudineConceptsPost-treatment isolatesStavudine resistanceStavudine therapyFirst-line combination therapyAmino acid changesUse of stavudineMonths of treatmentClinical HIV-1HIV-1 strainsNucleoside analoguesAcid changesProlonged therapyHIV patientsConsistent amino acid changesCombination therapyMulti-resistant phenotypeHIV-1Lower incidenceReverse transcriptase geneClinical isolatesTherapyDrug sensitivityPatientsTranscriptase geneCurrent report
1994
Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users
Alcabes P, Muñoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Annals Of Epidemiology 1994, 4: 17-26. PMID: 7911376, DOI: 10.1016/1047-2797(94)90038-8.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBaltimoreCD4-Positive T-LymphocytesCohort StudiesConfidence IntervalsHIV InfectionsHIV SeroprevalenceHomosexualityHumansIncidenceLeukocyte CountLife TablesMaleModels, StatisticalNew York CityPlatelet CountRegression AnalysisSubstance Abuse, IntravenousSurvival RateTime FactorsConceptsHIV infectionDrug usersImmunodeficiency syndromeMedian timeCombined cohortHomosexual menHuman immunodeficiency virus (HIV) infectionHuman immunodeficiency virus (HIV) epidemicPercent of CD4Immunodeficiency virus infectionIncident HIV infectionProduct-limit methodMarkers of maturityHIV incubation distributionsPlatelet countVirus infectionLarge cohortSeroconversionCohortInfectionConfidence intervalsIncubation distributionAIDSVirus epidemicPopulation groupsLaboratory markers and the risk of developing HIV-1 disease among injecting drug users
Alcabes P, Selwyn P, Davenny K, Hartel D, Buono D, Schoenbaum E, Klein R, Friedland G. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994, 8: 107-116. PMID: 7912083, DOI: 10.1097/00002030-199401000-00016.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultBiomarkersCD4-Positive T-LymphocytesCohort StudiesFemaleHIV InfectionsHIV-1HumansLeukocyte CountMaleProspective StudiesRisk FactorsSubstance Abuse, IntravenousTime FactorsConceptsCD4 lymphocyte countHIV-1-related outcomesLow CD4 lymphocyte countCD4 lymphocyte numbersPyogenic bacterial infectionsHIV-1 diseaseLymphocyte countLaboratory markersLymphocyte numbersClinical eventsAIDS diagnosisRelative riskDrug usersBacterial infectionsHIV-1-associated diseaseBeta 2M levelsSerum beta 2M levelsDifferent laboratory markersMultiple constitutional symptomsAIDS riskMethadone treatment programsPredictors of progressionHIV-1 infectionLow platelet countLower leukocyte counts
1993
Association of Baseline Neuropsychological Function and Progression of Illness Over 4 Years in HIV-Seropositive Individuals
Silberstein C, O’dowd M, Schoenbaum E, Friedland G, Chartock P, Feiner C, Mckegney F. Association of Baseline Neuropsychological Function and Progression of Illness Over 4 Years in HIV-Seropositive Individuals. Journal Of The Academy Of Consultation-Liaison Psychiatry 1993, 34: 502-505. PMID: 8284340, DOI: 10.1016/s0033-3182(93)71824-1.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeCentral Nervous SystemCentral Nervous System DiseasesCognition DisordersFemaleHIV SeropositivityHumansImmune SystemLongitudinal StudiesMaleNeuropsychological TestsConceptsHuman immunodeficiency virus (HIV) disease progressionHIV-positive asymptomatic patientsCentral nervous system impairmentHIV-seropositive individualsNervous system impairmentBaseline neuropsychological functionProgressive HIVAsymptomatic HIVAsymptomatic patientsPoorer baseline scoresImmunologic dysfunctionSystemic symptomsDisease progressionNeuropsychological dysfunctionBaseline scoresNeuropsychological functionHIVPatientsSystem impairmentStudy periodNeuropsychological testsNeuropsychological markersDysfunctionProgressionHigher scoresIncubation Period of Human Immunodeficiency Virus
Alcabes P, Muñoz A, Vlahov D, Friedland G. Incubation Period of Human Immunodeficiency Virus. Epidemiologic Reviews 1993, 15: 303-318. PMID: 8174659, DOI: 10.1093/oxfordjournals.epirev.a036122.Peer-Reviewed Original ResearchAcquired Immunodeficiency SyndromeCohort StudiesEpidemiologic MethodsHIV InfectionsHIV SeropositivityHIV-1HumansIncidencePrevalenceTime FactorsUnited States
1992
Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection
Selwyn P, Alcabes P, Hartel D, Buono D, Schoenbaum E, Klein R, Davenny K, Friedland G. Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 327: 1697-1703. PMID: 1359411, DOI: 10.1056/nejm199212103272401.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBacterial InfectionsCandidiasis, OralCD4-Positive T-LymphocytesFemaleFollow-Up StudiesHIV InfectionsHumansLeukocyte CountMaleMultivariate AnalysisNew York CityProportional Hazards ModelsProspective StudiesRacial GroupsSubstance Abuse, IntravenousZidovudineConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSInjection drug usersBacterial infectionsDisease progressionOral candidiasisVirus infectionSite primary medical careMultiple constitutional symptomsPyogenic bacterial infectionsHIV-seropositive patientsPercentage of CD4Cohort of patientsDiagnosis of AIDSMethadone treatment programsProportional hazards regressionProduct-limit survival analysisIncidence of AIDSPrimary medical careRate of progressionRisk of AIDSSeronegative patientsConstitutional symptomsSeropositive patients
1991
Demographic characteristics, drug use, and sexual behavior of i.v. drug user with AIDS in Bronx, New York.
Schrager L, Friedland G, Feiner C, Kahl P. Demographic characteristics, drug use, and sexual behavior of i.v. drug user with AIDS in Bronx, New York. Public Health Reports 1991, 106: 78-84. PMID: 1899944, PMCID: PMC1580205.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultCocaineFemaleHeroinHumansMaleNew York CityRisk FactorsSexual BehaviorSocial ClassSubstance Abuse, IntravenousConceptsDrug usersDemographic characteristicsDrug useHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionIntravenous drug usersMontefiore Medical CenterMethadone maintenance programSharing of needlesInjection of drugsSexual behaviorDrug use behaviorsDrug use practicesHIV infectionImmunodeficiency syndromeVirus infectionMedical CenterEpidemiologic informationShooting galleriesCocaine useAIDSInjection episodesSexual practicesEarly ageInfectionSurvival differences in patients with AIDS.
Friedland G, Saltzman B, Vileno J, Freeman K, Schrager L, Klein R. Survival differences in patients with AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 144-53. PMID: 1987352.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAge FactorsAgedEthnicityFemaleHumansIncomeMaleMiddle AgedOpportunistic InfectionsRacial GroupsRisk FactorsSubstance Abuse, IntravenousConceptsPneumocystis carinii pneumoniaFavorable survivalCarinii pneumoniaMale sexYounger ageRisk behaviorsInitial AIDS diagnosisSingle medical centerIntravenous drug usePoint of diagnosisInitial AIDSMedian survivalAIDS diagnosisBlack raceSurvival differencesKaposi's sarcomaMedical CenterClinical carePatientsDrug useAIDSSurvivalDiagnosisPowerful predictorMonths
1990
The Recovery of Mycobacterium avium Complex and Mycobacterium tuberculosis from Blood Specimens of AIDS Patients Using the Nonradiometric BACTEC NR 660 Medium
Motyl M, Saltzman B, Levi M, Mckitrick J, Friedland G, Klein R. The Recovery of Mycobacterium avium Complex and Mycobacterium tuberculosis from Blood Specimens of AIDS Patients Using the Nonradiometric BACTEC NR 660 Medium. American Journal Of Clinical Pathology 1990, 94: 84-86. PMID: 2113765, DOI: 10.1093/ajcp/94.1.84.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBacteriological TechniquesCulture MediaFemaleHumansMaleMycobacterium avium ComplexMycobacterium tuberculosisConceptsAIDS patientsMycobacterium avium complexAvium complexBlood culturesMycobacterial mediaM. tuberculosisMycobacterium tuberculosisFemale AIDS patientsAcid-fast stainAliquots of mediumM. avium complexMale patientsFast stainBlood specimensPositive culturesBlood culture mediaPatientsTuberculosisMicrobiology laboratoryMycobacterial growthSignificant differencesMycobacteriaReference strainsPercentBacteremia